• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".对《Ishaq MU等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”》的回应
J Endocr Soc. 2024 Dec 4;9(1):bvae218. doi: 10.1210/jendso/bvae218. eCollection 2024 Nov 26.
2
Letter to Editor From Ishaq MU et al: "Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease".伊沙克·穆等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”
J Endocr Soc. 2024 Dec 13;9(1):bvae217. doi: 10.1210/jendso/bvae217. eCollection 2024 Nov 26.
3
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标。
J Endocr Soc. 2024 Jul 8;8(8):bvae122. doi: 10.1210/jendso/bvae122. eCollection 2024 Jul 1.
4
Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.对霍洛维茨等人致编辑的信的回复，该信涉及达尔等人发表的“口服司美格鲁肽改善2型糖尿病患者的餐后血糖和脂质代谢，并延迟胃排空”一文。
Diabetes Obes Metab. 2021 Oct;23(10):2414-2416. doi: 10.1111/dom.14485. Epub 2021 Jul 28.
5
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.每周一次皮下注射司美格鲁肽可改善 2 型糖尿病患者的脂肪肝疾病：一项为期 52 周的前瞻性真实世界研究。
Nutrients. 2022 Nov 4;14(21):4673. doi: 10.3390/nu14214673.
6
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.司美格鲁肽可改善患有代谢功能障碍相关脂肪性肝病的肥胖和2型糖尿病小鼠的肝脏脂肪变性及从头脂肪生成标志物。
Int J Mol Sci. 2024 Mar 4;25(5):2961. doi: 10.3390/ijms25052961.
7
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.司美格鲁肽与非酒精性脂肪性肝病合并2型糖尿病患者肝脏不良结局风险：一项多机构队列研究
Hepatol Int. 2025 Apr;19(2):395-404. doi: 10.1007/s12072-024-10752-9. Epub 2024 Nov 27.
8
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.一项评估 efinopegdutide 在非酒精性脂肪性肝病患者中的疗效和安全性的 IIa 期主动对照研究。
J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22.
9
The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.司美格鲁肽联合二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者肝脏炎症和胰岛β细胞功能的影响。
J Diabetes Complications. 2025 Feb;39(2):108932. doi: 10.1016/j.jdiacomp.2024.108932. Epub 2024 Dec 9.
10
Semaglutide alters gut microbiota and improves NAFLD in db/db mice.司美格鲁肽改变肠道微生物群并改善 db/db 小鼠的非酒精性脂肪性肝病。
Biochem Biophys Res Commun. 2024 May 28;710:149882. doi: 10.1016/j.bbrc.2024.149882. Epub 2024 Apr 3.

本文引用的文献

1
Letter to Editor From Ishaq MU et al: "Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease".伊沙克·穆等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”
J Endocr Soc. 2024 Dec 13;9(1):bvae217. doi: 10.1210/jendso/bvae217. eCollection 2024 Nov 26.
2
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
3
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.代谢相关脂肪性肝病时代非侵入性评分和血清生物标志物在脂肪性肝病中的应用：从非酒精性脂肪性肝病到代谢相关脂肪性肝病和脂肪性肝病的综合评价。
Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29.
4
Non-invasive tests of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的无创性检查。
Chin Med J (Engl). 2022 Jan 27;135(5):532-546. doi: 10.1097/CM9.0000000000002027.
5
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者脂肪变性生物标志物的性能与局限性
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22. doi: 10.1111/apt.12963. Epub 2014 Sep 29.
6
Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.肝脂肪变性指数：一种反映非酒精性脂肪性肝病的简单筛查工具。
Dig Liver Dis. 2010 Jul;42(7):503-8. doi: 10.1016/j.dld.2009.08.002. Epub 2009 Sep 18.

Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".

作者信息

Korakas Emmanouil, Kountouri Aikaterini, Pavlidis George, Oikonomou Evangelos, Vrentzos Emmanouil, Michalopoulou Eleni, Tsigkou Vasiliki, Katogiannis Konstantinos, Pliouta Loukia, Balampanis Konstantinos, Pililis Sotirios, Malandris Konstantinos, Tsapas Apostolos, Siasos Gerasimos, Ikonomidis Ignatios, Lambadiari Vaia

机构信息

2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital Medical School, National and Kapodistrian University of Athens,12462 Athens, Greece.

出版信息

J Endocr Soc. 2024 Dec 4;9(1):bvae218. doi: 10.1210/jendso/bvae218. eCollection 2024 Nov 26.

DOI:10.1210/jendso/bvae218
PMID:39711847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11663492/
Abstract
摘要